The 0.05% trim by Dodge & Cox is a routine rebalancing move, not a conviction change. Monitor the next 13F filing for the full Q2 2026 position size. No immediate trading action warranted.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $52.81entry
- T+1 · 5mo ago −0.74%α −1.52% · $52.42
- T+5 · 4mo ago +0.53%α −0.86% · $53.09
- T+20 · 4mo ago −2.76%α −2.49% · $51.35
- T+60 · 8w ago −3.96%α −8.33% · $50.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dodge & Cox, a top-3 institutional holder of GSK, disclosed a reduction in its voting rights stake from 5.01% to 4.96%, crossing below the 5% UK notification threshold. The sale of approximately 2 million shares (based on the 0.05% decline) is a modest trim by a long-term value manager, not a material bearish signal for a $107B pharma company.
Key Facts
- Dodge & Cox reduced its GSK voting rights stake from 5.01% to 4.96%, crossing below the 5% threshold on June 24, 2026.
- Total voting rights held: 201,065,668 (4.96% of total), split between ordinary shares (88,816,040; 2.19%) and ADRs (112,249,628; 2.77%).
- No financial instruments (options, swaps, etc.) were reported, the entire position is in common equity.
- Dodge & Cox remains a top-3 institutional holder per the 13F snapshot ($3.2B position as of Q1 2026).
Financial Impact
Stake reduction of ~0.05% of total voting rights, representing roughly 2 million shares or ~$80-100M at current prices, a routine portfolio trim for a $3.2B position.
Risk Factors
- Further selling by Dodge & Cox could signal reduced conviction, but the current 0.05% reduction is immaterial.
- The 20-F annual report (filed 115 days ago) provides the broader financial context, no recent earnings or guidance updates are available in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006269 |
| Document: 0001654954-26-006269-index-headers.html | 0001654954-26-006269 |
| Document: 0001654954-26-006269-index.html | 0001654954-26-006269 |
| Document: 0001654954-26-006269.txt | 0001654954-26-006269 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers